Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?

Key Points

• Vor Biopharma shares fell 5.4% to about $23.74, with trading volume 81% below its average daily level.
• Analysts maintain a Moderate Buy consensus, with an average price target of $43.38, although the company’s latest quarterly loss of $0.80 per share missed estimates by $0.11.
• Institutional investors own 97.29% of the stock, while Vor continues developing its lead gene-edited cell therapy candidate, VOR33, for relapsed or refractory AML and high-risk MDS.

Shares of Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) traded down 5.4% on Wednesday . The company traded as low as $23.59 and last traded at $23.7420. 192,494 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 1,028,723 shares. The stock had previously closed at $25.10.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Vor Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. HC Wainwright restated a "buy" rating and set a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Wedbush lifted their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $43.38.

Vor Biopharma Stock Down 5.3%

The stock's fifty day moving average is $21.55 and its two-hundred day moving average is $17.27.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). As a group, analysts predict that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently bought and sold shares of VOR. Bank of America Corp DE boosted its stake in Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock valued at $2,014,000 after buying an additional 112,496 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Vor Biopharma in the 1st quarter valued at $2,298,000. UBS Group AG grew its stake in shares of Vor Biopharma by 284.8% during the fourth quarter. UBS Group AG now owns 292,118 shares of the company's stock valued at $3,821,000 after buying an additional 216,209 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Vor Biopharma in the fourth quarter valued at approximately $33,275,000. Finally, Braidwell LP boosted its position in Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company's stock valued at $10,551,000 after buying an additional 106,330 shares during the period. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.